Skip to main content
ACS Medicinal Chemistry Letters logoLink to ACS Medicinal Chemistry Letters
. 2025 Oct 8;16(11):2138–2146. doi: 10.1021/acsmedchemlett.5c00472

Synthesis and Evaluation of [177Lu]Lu-Labeled-NLS-Trastuzumab Conjugate for Targeting of HER2 Positive Metastatic Breast Cancer: Evaluating the Effect on Intracellular Localization

Soumi Kolay †, V Kusum Vats †,‡, Rohit Sharma †, Mohini Guleria †,‡,*, Jeyachitra Amirdhanayagam †, Naveen Kumar †,‡, Manoj Kumbhakar §, Archana Mukherjee †,‡, Tapas Das †,‡,*
PMCID: PMC12621021  PMID: 41256994

Abstract

[177Lu]­Lu-DOTA-Trastuzumab is currently under clinical evaluation for radioimmunotherapy (RIT) for HER2-positive breast cancer. This study aimed to enhance its internalization by modifying Trastuzumab with a nuclear localization signal (NLS: PKKKRKV). The NLS, bearing a terminal azide group, was synthesized via solid-phase peptide synthesis. DOTA, a chelator for 177Lu, was incorporated at the α-amino group of lysine at the NLS’s proline end, allowing UV–vis-based drug-to-antibody ratio (DAR) estimation. Both DOTA-Trastuzumab and DOTA-NLS-Trastuzumab, along with their [177Lu]­Lu-labeled counterparts, were synthesized. In vitro studies in HER2-positive SK-OV-3 and SK-BR-3 cells showed an enhanced internalization of the NLS-modified conjugate. However, ex vivo and in vivo evaluation in SCID mice revealed lower tumor and nontarget organ accumulation for [177Lu]­Lu-DOTA-NLS-Trastuzumab compared to [177Lu]­Lu-DOTA-Trastuzumab, indicating altered biodistribution despite improved cellular uptake.

Keywords: Trastuzumab, NLS, DOTA, [177Lu]Lu-Trastuzumab, cell-internalization


graphic file with name ml5c00472_0013.jpg


graphic file with name ml5c00472_0012.jpg


Trastuzumab, a monoclonal antibody (IgG) has been approved by US-FDA (United States Food and Drug Administration) for immunotherapy of the HER2 (Human epidermal growth factor receptor-2) positive breast cancer. − Use of Trastuzumab for immunotherapy has certain limitations involving cardiotoxicity and other issues related to receptor heterogeneity and their down-regulation during treatment. To alleviate this, the use of Trastuzumab in radiolabeled form has been envisaged, wherein the antibody is radiolabeled with a suitable therapeutic radionuclide for exerting therapeutic effects. The aforementioned treatment is termed as “radioimmunotherapy” (RIT), where unlike immunotherapy; the associated radionuclide is responsible for therapeutic efficacy whereas the monoclonal antibody acts as the targeting vector. ,− Though radioimmunotherapy employing radiolabeled antibodies has reached clinical domain in the recent time, therapeutic efficacy of this modality often gets compromised due to the inadequate tissue penetration resulting in lower intracellular accumulation. ,,

In the present work, an attempt has been made to functionally modify Trastuzumab with a Nuclear Localization Signal (NLS) peptide, which is rich in positively charged amino acids, with an aim to augment the cellular uptake of the radiolabeled antibody. The cationic nature of NLS is envisaged to facilitate the transport of molecular cargo across the cellular membrane. − A seven amino acid sequence, namely, PKKKRKV (Pro-Lys-Lys-Lys-Arg-Lys-Val), belongs to the family of NLS peptides and, like others in this family, is well-recognized by the Nuclear Pore Complex (NPC). Therefore, conjugation of various molecular cargos such as small molecules, peptides and proteins to this sequence has been envisaged for promoting their intracellular accumulation. With a similar objective, Trastuzumab was conjugated with the NLS peptide sequence during the course of present work. Additionally, an attempt was also made to strategically incorporate a DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) derivative while building up the NLS peptide sequence so as to use this moiety for estimation of DAR (Drug to Antibody ratio) postconjugation of NLS with Trastuzumab. The presence of a DOTA moiety in the peptide chain (covalently attached to the antibody) could also be utilized for radiolabeling with Lutetium-177 without compromising the additional lysine residues in the antibody for coupling with DOTA.

A copper-free click chemistry reaction was utilized for enabling the conjugation of DOTA-Azide-NLS peptide with DBCO (dibenzocyclooctyne) modified Trastuzumab to prepare the DOTA-NLS-Trastuzumab conjugate. To perform a comparative evaluation, the DOTA-Trastuzumab conjugate was also synthesized along with NLS modified Trastuzumab in this work. Postsynthesis, DOTA-Trastuzumab and DOTA-NLS-Trastuzumab were radiolabeled with 177Lu [Eβmax = 497 keV, T1/2 = 6.73 d, Eγ = 208 keV (11%), 113 keV (6.4%)], a well-established therapeutic radionuclide used extensively for the radio-therapeutic treatment of patients suffering from a variety of cancers and other nononcological maladies. − First, DOTA-Azide-NLS was synthesized by following the manual solid phase peptide synthesis method. NLS (PKKKRKV) sequence was synthesized and was modified further at proline end to introduce Fmoc-Lys­(N3)-OH. The lysine modified NLS sequence was deprotected at α-amino group to introduce DOTA moiety (DOTA-tris­(t-Bu)­ester). Subsequently, the resin was treated with the cocktail mixture of TFA/H2O/TIPS (95:2.5:2.5 v/v/v) for cleavage of the peptide from the solid phase with simultaneous deprotection of side chain groups (Figure (a) and (b)). The crude peptide thus obtained was purified using semipreparative HPLC.

1.

1

(a) Synthetic scheme adopted to obtain Azide-functionalized NLS sequence (DOTA-Azide-NLS) starting with MBHA resin to build up Fmoc-PKKKRKV sequence followed by a three-step synthetic scheme: (i) 20% piperidine, Fmoc-Lys­(N3)-OH, DMF, rt, 2 h (ii) 20% piperidine, DOTA-tris­(tert-butyl)­ester, DMF, rt, 2 h (iii) 95% TFA, 2.5% TIPS, 2.5% H2O, rt, 2 h, and (b) final structure of DOTA-Azide-NLS.

The purified fractions were analyzed by HR-MS for the selection of eluted fractions that contain the desired product. In HR-MS, mass peaks at 474.9713 (m/3) and 356.4794 (m/4) corresponding to [M+3H]3+ and [M+4H]4+ molecular ions of the DOTA-Azide-NLS sequence were observed (Figure (a)). The purified peptide sequence was also characterized by FT-IR spectroscopy wherein a peak at 2102 cm–1, corresponding to the N3 group, in the peptide sequence was observed (Figure (b)).

2.

2

(a) HR-MS spectrum depicting the mass peaks obtained corresponding to [M+3H] and [M+4H] molecular ions for DOTA-Azide-NLS peptide, and (b) FT-IR spectrum recorded for DOTA-Azide-NLS peptide (signal at 2102 cm–1 corresponds to azide functional group).

DOTA-Azide-NLS peptide was utilized for conjugation with Trastuzumab via DBCO-PEG4-Acid linker by employing copper-free click chemistry reaction wherein the octyne ring reacts with the azido moiety of the DOTA-Azide-NLS resulting in formation of a triazole ring (Figure (a) and (b)).

3.

3

Pictorial representation of reaction scheme utilized for synthesis of: (a) Trastuzumab-DBCO conjugate and (b) DOTA-NLS-Trastuzumab conjugate.

Trastuzumab was also conjugated separately with DOTA employing the p-SCN-benzyl-DOTA derivative wherein the -SCN group of DOTA was conjugated with the -NH2 group of the lysine moieties present in the structure of Trastuzumab resulting in the formation of a thiourea linker.

Both DOTA-Trastuzumab and DOTA-NLS-Trastuzumab conjugates were analyzed for DOTA as well as for estimation protein content by Arsenazo III dye-based UV–vis spectrophotometric analysis and Bradford assay, respectively. It was found from the calibration plots of the aforementioned assays that the average number of DOTA present per Trastuzumab moiety in the DOTA-Trastuzumab conjugate is ∼6.2 ± 0.8 whereas the same was estimated to be ∼5.0 ± 1.0 in DOTA-NLS-Trastuzumab (Figure (a) and (b)).

4.

4

Calibration plots: (a) for determination of protein content using Bradford assay and (b) for estimation of DOTA content using Arsenazo III dye-based UV–vis spectrophotometric analysis.

Paper chromatography was used for determining the percentage radiochemical yield of [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab. In PC (n = 3), the radiolabeled antibody in both the radioformulations remained at the origin (Rf = 0.0–0.1), whereas free 177Lu moved along with the solvent up to the solvent front (Rf = 1.0) under identical conditions (Figure ). The percentage radiochemical yield for [177Lu]­Lu-DOTA-Trastuzumab was found to be 95.9 ± 1.0% while the same for [177Lu]­Lu-DOTA-NLS-Trastuzumab was determined to be 60.2 ± 2.1%. After purification through PD-10 column, the percentage radiochemical purity of the [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab was observed to be 99.2 ± 0.2% and 98.0 ± 1.0%, respectively.

5.

5

Radio-PC profiles depicting retention factors (Rf): (a) Free/unlabeled [177Lu]Lu (Rf = 1.0), (b) [177Lu]­Lu-DOTA-NLS-Trastuzumab (Rf = 0.0–0.1), and (c) [177Lu]­Lu-DOTA-Trastuzumab (Rf = 0.0–0.1).

The LogDO/W values of [177Lu]­Lu-DOTA-NLS-Trastuzumab and [177Lu]­Lu-DOTA-Trastuzumab were determined by following the standard octanol/water partitioning protocol. The measured octanol/water distribution coefficients (LogDo/w) were found to be −2.23 ± 0.15 for [177Lu]­Lu-DOTA-NLS-Trastuzumab and −2.40 ± 0.11 for [177Lu]­Lu-DOTA-Trastuzumab.

The in vitro stability of [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab in phosphate-buffered saline (PBS) was evaluated at various postpreparation time points: 3 h, 1 d, 2 d, and 7 d. [177Lu]­Lu-DOTA-Trastuzumab demonstrated a relatively higher stability than [177Lu]­Lu-DOTA-NLS-Trastuzumab, particularly at later time points. The radiochemical purity of [177Lu]­Lu-DOTA-Trastuzumab was 98.5 ± 0.3%, 97.9 ± 1.4%, 95.4 ± 1.5%, and 78.3 ± 3.5% at 3 h, 1 d, 2 d, and 7 d, respectively. In contrast, [177Lu]­Lu-DOTA-NLS-Trastuzumab showed radiochemical purities of 97.0 ± 0.9%, 92.7 ± 2.3%, 75.3 ± 2.5%, and 60.5 ± 4.6% at the corresponding time points.

In SK-OV-3 cells, [177Lu]­Lu-DOTA-Trastuzumab exhibited a binding of 50.99 ± 0.88% and 48.01 ± 0.94% at 5 and 10 nM concentration, respectively; whereas the same was observed to be 37.75 ± 0.94% and 36.23 ± 0.68% for [177Lu]­Lu-DOTA-NLS-Trastuzumab. However, a reverse trend was observed for percentage cell internalization wherein [177Lu]­Lu-DOTA-NLS-Trastuzumab exhibited higher internalization of the cell bound activity (83.92 ± 1.94 and 90.03 ± 1.78%, respectively) compared to that observed in the case of [177Lu]­Lu-DOTA-Trastuzumab (72.92 ± 0.89% and 73.94 ± 0.94%, respectively) at both ligand concentrations. In SK-BR-3 cells too, a similar trend was observed where [177Lu]­Lu-DOTA-Trastuzumab exhibited a higher cell binding (18.10 ± 0.81%) compared to that exhibited by [177Lu]­Lu-DOTA-NLS-Trastuzumab (14.16 ± 0.65%) and lower internalization of the cell bound activity (36.74 ± 1.74% and 49.64 ± 2.58%, respectively). The percentage cell binding and cell internalization for both the radiolabeled compounds in SK-OV-3 and SK-BR-3 cell lines are shown in Figure (a) and (b) and Figure .

6.

6

Graphical representation of (a) percentage cell binding and (b) percentage internalization of the cell bound activity (% internalization*) exhibited by [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab, respectively, in SK-OV-3 cells.

7.

7

Graphical representation of percentage cell binding and percentage internalization* (internalization* represents percentage cell internalization of the cell bound activity) exhibited by [177Lu]­Lu-DOTA-Trastuzumab [5 nM] and [177Lu]­Lu-DOTA-NLS-Trastuzumab [5 nM] in SK-BR-3 cells.

Binding affinity studies in SK-OV-3 cells demonstrated that both [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab exhibited nanomolar binding affinities. The dissociation constant (Kd) values were found to be 13.03 ± 1.13 nM for [177Lu]­Lu-DOTA-Trastuzumab and 25.28 ± 3.31 nM for [177Lu]­Lu-DOTA-NLS-Trastuzumab.

Immunoreactive fraction corresponding to both the radiolabeled complexes was also determined in the present work using a graphical method. An IRF of 45.86% was obtained for [177Lu]­Lu-DOTA-NLS-Trastuzumab, while the same was observed to be around 93.33% for [177Lu]­Lu-DOTA-Trastuzumab.

Fluorescence imaging studies performed in SK-OV-3 cells showed that DOTA-Trastuzumab predominantly accumulates in the cell periphery, whereas DOTA-NLS-Trastuzumab was found to localize in the intracellular environment (Figure (a) and (b), respectively). When the same experiments were repeated in HER2 negative MDA-MB-231 cells, both complexes failed to exhibit any observable binding (Figure (c) and (d), respectively).

8.

8

Cell images exhibiting the accumulation of DOTA-Trastuzumab and DOTA-NLS-Trastuzumab (a,b) in SK-BR-3 (HER2 positive) and negligible localization (c,d) in MDA-MB-231 (HER2 negative) cells, respectively.

Biodistribution studies revealed significant accumulation of [177Lu]­Lu-DOTA-Trastuzumab in organs such as liver (8.21 ± 0.68 %IA/g) and spleen (6.37 ± 3.03% IA/g, respectively) at 48 h postadministration (Figure (a)). However, for [177Lu]­Lu-DOTA-NLS-Trastuzumab the liver and spleen accumulations were observed to be 9.28 ± 3.15 and 3.64 ± 1.12% IA/g at 48 h postadministration, respectively (Figure (b)). Contrary to [177Lu]­Lu-DOTA-Trastuzumab, [177Lu]­Lu-DOTA-NLS-Trastuzumab exhibited significantly lower uptake in blood (3.60 ± 0.99 and 0.12 ± 0.01% IA/g, respectively). Tumor uptake of 13.11 ± 4.20% IA/g was observed for [177Lu]­Lu-DOTA-Trastuzumab, while the same for [177Lu]­Lu-DOTA-NLS-Trastuzumab was found to be 2.26 ± 0.20% IA/g at 48 h postadministration (Figure (a) and (b)). Overall, [177Lu]­Lu-DOTA-NLS-Trastuzumab exhibited significantly lower uptake in nontarget organs such as blood, lungs, and heart (p < 0.05) and a higher uptake in kidneys (p < 0.05) compared to non-NLS conjugated complex (Figure ).

9.

9

Graphs (a) and (b) depicting the percentage injected activity per gram of organ/tissue (% IA/g) in major organs of a small animal model, observed for [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab, at 48 h p.i.

10.

10

Graph depicting comparative accumulation (%IA/g) of [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab in organs viz. blood, lungs, heart, spleen, kidney, and tumor, at 48 h postadministration.

The in vivo stability of [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab was assessed by paper chromatography analysis of mouse blood samples collected at various time points postadministration. At 3 h postinjection, the radiochemical purities of [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab were 78.3 ± 5.0% and 75.4 ± 3.5%, respectively. By day 7, the values declined to 73.35 ± 3.53% and 56.98 ± 2.59%, respectively. These results indicate that both radioconjugates exhibit reasonably good in vivo stability; however, [177Lu]­Lu-DOTA-Trastuzumab demonstrates a comparatively greater stability at extended time points.

Imaging studies performed in tumor-bearing SCID mice showed accumulation of the radiotracers ([177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab) in the liver and spleen at the early time point (24 h p.i.). Uptake was also observed in tumor mass; however, tumor uptake was found to be relatively more intense in the case of [177Lu]­Lu-DOTA-Trastuzumab than that observed for [177Lu]­Lu-DOTA-NLS-Trastuzumab. Even at 6 days postadministration, not much decline in the activity accumulated in the regions comprising liver and spleen was observed for both the radiotracers. However, a significant increase in the tumor accumulation was seen with time for both the radiolabeled complexes. The gamma scans recorded for [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab at different postadministration time-points are shown in Figure .

11.

11

Serial gamma scans of the tumor bearing animals administered with [177Lu]­Lu-DOTA-NLS-Trastuzumab (left) and [177Lu]­Lu-DOTA-Trastuzumab (right) recorded at three different postadministration time points, viz., 24 h, 48 h, and 6 d, respectively.

Trastuzumab has been radiolabeled with a variety of radionuclides and both preclinical as well as clinical studies have been documented in the contemporary literature. ,− Radiation cross-fire effect due to beta particles emanating from the radionuclide attached with antibody is envisaged to alleviate the limitations associated with conventional immunotherapy. Many reasons have been cited for poor response during immunotherapy viz. down-regulation of target receptor antigens, receptor heterogeneity, etc. However, during radioimmunotherapy, the radiation cross-fire as mentioned earlier can kill those cells too wherein antibody has failed to bind. Nonetheless, radioimmunotherapy too suffers from poor tissue penetration of antibodies, thereby leading to suboptimal therapeutic effects. To overcome this drawback, functional modification of antibodies using secondary moieties such as, charged peptides have been documented in the past. Constanini et. al documented the preparation and evaluation of 111In-labeled-peptide-Trastuzumab derivatives by using multimer extended NLS scaffolds, wherein they observed an enhancement in the therapeutic efficacy upon functional modification compared to unmodified Trastuzumab.

In the present work, Trastuzumab was functionally modified with in-house synthesized NLS utilizing a copper free click chemistry reaction with an aim to enhance its cellular localization, and the same was radiolabeled with a therapeutic radionuclide, namely, 177Lu to further augment the therapeutic efficacy. Additionally, DOTA, a bifunctional chelator used for radiolabeling with 177Lu, was attached in the same amino acid chain that was utilized to build up NLS peptide. This strategy provided two advantages: first, DOTA and NLS being the same entity (as DOTA-azide-NLS) enabled the determination of DAR utilizing a well-established Arsenazo III dye-based UV–vis spectrophotometric assay, and second, there is no need to have separate -NH2 binding sites in antibody structures for conjugation of DOTA required for radiolabeling, thereby reducing the probability of the further loss in immunoreactivity. In this study, two radiolabeled complexes of Trastuzumab, namely, DOTA-Trastuzumab and DOTA-NLS-Trastuzumab (NLS modified Trastuzumab), were synthesized and characterized for average number of DOTA molecules attached per antibody molecule and DAR. During fluorescence imaging studies, DOTA-NLS-Trastuzumab exhibited substantially higher intracellular localization compared to DOTA-Trastuzumab, wherein the latter remained majorly confined to the cellular membrane. This observation indicated the augmentation in cell permeability of Trastuzumab postconjugation with NLS. Further, both the conjugates were radiolabeled with 177Lu with high radiochemical purity (>95%). Postpreparation, both [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab (NLS modified Trastuzumab) were evaluated for differential uptake in two different HER2 positive cancer cells (SK-OV-3 and SK-BR-3). In cell studies, [177Lu]­Lu-DOTA-NLS-Trastuzumab exhibited a relatively lower level of cell binding than that observed for [177Lu]­Lu-DOTA-Trastuzumab. However, a higher internalization of cell bound activity was observed in case of former complex in both the cell lines thereby complementing the observation made during cell imaging studies. Ex vivo studies with [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab performed in tumor bearing SCID mice revealed significantly lower accumulation (p < 0.05) of the NLS modified Trastuzumab in nontarget organs such as blood, heart, and lungs compared to unmodified Trastuzumab. The observed high nonspecific uptake in the liver for both the radiotracers is a well-established characteristic of antibody metabolism. This is primarily due to the presence of Fc gamma receptors on Kupffer cells in the liver, which preferentially metabolize immunoglobulins. , The difference in the liver uptake of both [177Lu]­Lu-DOTA-NLS-Trastuzumab and [177Lu]­Lu-DOTA-Trastuzumab was found to be statistically nonsignificant (p > 0.05), indicating similar hepatic processing of both the conjugates. However, the relatively higher kidney uptake observed for [177Lu]­Lu-DOTA-NLS-Trastuzumab compared to its unmodified counterpart is likely a result of in vivo degradation of the radiolabeled construct. Specifically, it is plausible that the immunoglobulin portion of the NLS-modified conjugate is metabolized in the liver, while the radiolabeled NLS fragment, once cleaved, accumulates in the kidneys. This interpretation is supported by our previous study, in which a separately synthesized [177Lu]­Lu-DOTA-NLS complex exhibited notably high kidney uptake and prolonged renal retention in animals.

However, substantially lower uptake (p < 0.05) in tumor was observed for [177Lu]­Lu-DOTA-NLS-Trastuzumab compared to [177Lu]­Lu-DOTA-Trastuzumab. This observation was further supplemented by the results of serial in vivo gamma scans acquired at different postadministration time-points (up to 6 days p.i.). The relatively lower tumor accumulation of [177Lu]­Lu-DOTA-NLS-Trastuzumab compared to [177Lu]­Lu-DOTA-Trastuzumab both during ex vivo and in vivo experiments could be attributed to rapid clearance of the former from the blood circulation thereby leading to lesser distribution in the tumorous mass. During the determination of immunoreactive fraction (IRF) in SK-OV-3 cells, a markedly lower IRF was observed for [177Lu]­Lu-DOTA-NLS-Trastuzumab (45.86%) compared to [177Lu]­Lu-DOTA-Trastuzumab (93.33%). This significant reduction suggests an additional contributing factor, beyond the decreased blood retention, to the reduced in vivo tumor uptake of the NLS-conjugated complex. Specifically, the functional integrity of the antibody, with respect to HER2 receptor binding, appears to have been compromised following NLS conjugation. While the functional modification of the antibody yielded encouraging outcomes in in vitro experiments, the low tumor accumulation observed in in vivo studies remains a major limitation, impeding the realization of the intended objectives of the present study.

In summary, NLS modified Trastuzumab exhibited relatively lower cell binding but a significantly higher internalization compared with DOTA-Trastuzumab during in vitro studies. However, ex vivo studies with [177Lu]­Lu-DOTA-Trastuzumab and [177Lu]­Lu-DOTA-NLS-Trastuzumab performed in a small animal model revealed significantly lower accumulation of the NLS modified Trastuzumab in the nontarget organs as well as in tumor compared to unmodified Trastuzumab indicating reduction of the tumor targeting ability of the radiolabeled Trastuzumab in vivo postfunctional modification.

Supplementary Material

ml5c00472_si_001.pdf (159.1KB, pdf)

Acknowledgments

The authors gratefully acknowledge Dr. Y. K. Bhardwaj, Associate Director, Radiochemistry and Isotope Group (RC&IG), Bhabha Atomic Research Centre (BARC) for his constant encouragement and unwavering support. The authors are thankful to Radiochemicals Section of Radiopharmaceuticals Division (RPhD), BARC for providing [177Lu]LuCl3 used in the present work. The authors also express sincere gratitude toward Mr. Viju Chirayil, RPhD, BARC for his help in performing the mass analyses (HR-MS). The authors are grateful to Dr. Suresh Subramanian, RPhD, BARC for his guidance and help in recording the scintigraphic images of the animals. The authors also acknowledge Miss Swati Dhavale, RPhD, BARC for her help in performing the ex vivo studies.

Glossary

Abbreviations

RIT

Radioimmuno therapy

NLS

Nuclear localization signal

DAR

Drug to antibody ratio

BFCA

Bifunctional chelating agent

DOTA

1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetracetic acid

DBCO

Dibenzocyclooctyne

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00472.

  • Details regarding materials and methods, detailed synthetic procedures and characterization (FT-IR, HR-MS, HPLC, radio-TLC chromatograms) and protocols followed for radiolabeling, in vitro, in vivo and ex vivo studies (PDF)

Bhabha Atomic Research Centre (BARC) is a constituent unit of Department of Atomic Energy (DAE), Government of India and all research activities carried out at the Centre are fully funded by Government of India.

The authors declare no competing financial interest.

This study involves the use of radioactive materials, which shall be handled solely by qualified personnel. All handling must be performed in designated facilities equipped for radioactive substances, adhering strictly to established safety protocols.

References

  1. Ayoub N. M., Al-Shami K. M., Yaghan R. J.. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer. 2019;11:53–69. doi: 10.2147/BCTT.S175360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Holgado E., Perez-Garcia J., Gion M., Cortes J.. Is there a role for immunotherapy in HER2-positive breast cancer? NPJ. Breast Cancer. 2018;4(1):1–3. doi: 10.1038/s41523-018-0072-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bhusari P., Vatsa R., Singh G., Parmar M., Bal A., Dhawan D., Mittal B. R., Shukla J.. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients. Int. J. Cancer. 2017;140(4):938–947. doi: 10.1002/ijc.30500. [DOI] [PubMed] [Google Scholar]
  4. Le X. F., Pruefer F., Bast R. C. Jr. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathway. Cell Cycle. 2005;4(1):87–95. doi: 10.4161/cc.4.1.1360. [DOI] [PubMed] [Google Scholar]
  5. Larson S. M., Carrasquillo J. A., Cheung N. K. V., Press O. W.. Radioimmunotherapy of human tumours. Nat. Rev. Cancer. 2015;15(6):347–360. doi: 10.1038/nrc3925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kawashima H.. Radioimmunotherapy: A specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. Sci. World J. 2014;2014:1. doi: 10.1155/2014/492061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ray G. L., Baidoo K. E., Keller L. M. M., Albert P. S., Brechbiel M. W., Milenic D.. Pre-clinical assessment of 177Lu-labeled trastuzumab targeting HER2 for treatment and management of cancer patients with disseminated intraperitoneal disease. Pharmaceuticals. 2012;5(1):1–15. doi: 10.3390/ph5010001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kameswaran M., Pandey U., Gamre N., Sarma H. D., Dash A.. Preparation of 177Lu-trastuzumab injection for treatment of breast cancer. Appl. Radiat. Isot. 2019;148:184–190. doi: 10.1016/j.apradiso.2019.04.002. [DOI] [PubMed] [Google Scholar]
  9. Guleria M., Sharma R., Amirdhanayagam J., Sarma H. D., Rangarajan V., Dash A., Das T.. Formulation and clinical translation of [177Lu]­Lu-trastuzumab for Radioimmunotheranostics of metastatic breast cancer. RSC Med. Chem. 2021;12(2):263–277. doi: 10.1039/D0MD00319K. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chakraborty A., Mitra A., Sahu S., Tawate M., Lad S., Kamaldeep, Rakshit S., Bannore T. U., Gaikwad S., Dhotre G., Ray M. K., Damle A., Basu S., Banerjee S.. Intricacies in the Preparation of Patient Doses of [177Lu]­Lu-Rituximab and [177Lu]­Lu-Trastuzumab Using Low Specific Activity [177Lu]­LuCl3: Methodological Aspects. Mol. Imaging Biol. 2024;26(1):61–80. doi: 10.1007/s11307-023-01846-1. [DOI] [PubMed] [Google Scholar]
  11. Zhang B., Wang M., Sun L., Liu j., Yin L., Xia M., Zhang L., Liu X., Cheng Y.. Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs? J. Med. Chem. 2024;67(14):11469–11487. doi: 10.1021/acs.jmedchem.4c00106. [DOI] [PubMed] [Google Scholar]
  12. Ragin A. D., Morgan R. A., Chmielewski J.. Cellular import mediated by nuclear localization signal peptide sequences. Chem. Biol. 2002;9(8):943–948. doi: 10.1016/S1074-5521(02)00189-8. [DOI] [PubMed] [Google Scholar]
  13. Sibrian-Vazquez M., Jensen T. J., Vicente M. G. H.. Influence of the number and distribution of NLS peptides on the photosensitizing activity of multimeric porphyrin-NLS. Org. Biomol. Chem. 2010;8(5):1160–1172. doi: 10.1039/b917280g. [DOI] [PubMed] [Google Scholar]
  14. Eguchi A., Furusawa H., Yamamoto A., Akuta T., Hasegawa M., Okahata Y., Nakanishi M.. Optimization of nuclear localization signal for nuclear transport of DNA-encapsulating particles. J. Controlled Release. 2005;104(3):507–519. doi: 10.1016/j.jconrel.2005.02.019. [DOI] [PubMed] [Google Scholar]
  15. Zanta M. A., Belguise-Valladier P., Behr J.-P.. Gene delivery: A single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc. Natl. Acad. Sci. U.S.A. 1999;96(1):91–96. doi: 10.1073/pnas.96.1.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dash A., Pillai M. R. A., Knapp F. F.. Production of 177Lu for Targeted Radionuclide Therapy: Available Options. J. Nucl. Med. Mol. Imaging. 2015;49(2):85–107. doi: 10.1007/s13139-014-0315-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pillai M. R. A., Chakraborty S., Das T., Venkatesh M., Ramamoorthy N.. Production logistics of 177Lu for radionuclide therapy. Appl. Radiat. Isot. 2003;59(2–3):109–118. doi: 10.1016/S0969-8043(03)00158-1. [DOI] [PubMed] [Google Scholar]
  18. Banerjee S., Das T., Chakraborty S., Venkatesh M.. Emergence and present status of Lu-177 in targeted radiotherapy: the Indian scenario. Radiochim. Acta. 2012;100:115–126. doi: 10.1524/ract.2011.1843. [DOI] [Google Scholar]
  19. Rasaneh S., Rajabi H., Babaei M. H., Daha F. J., Salouti M.. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl. Med. Biol. 2009;36(4):363–369. doi: 10.1016/j.nucmedbio.2009.01.015. [DOI] [PubMed] [Google Scholar]
  20. Guleria M., Das T., Kumar C., Sharma R., Amirdhanayagam J., Sarma H. D., Dash A.. Effect of number of bifunctional chelating agents on the pharmacokinetics and immunoreactivity of 177Lu-labeled Rituximab: A systemic study. Anticancer Agents Med. Chem. 2018;18(1):146–153. doi: 10.2174/1871520617666170725164530. [DOI] [PubMed] [Google Scholar]
  21. Chakraborty S., Vimalnath K. V., Rajeswari A., Shinto A., Sarma H. D., Kamaleshwaran K., Thirumalaisamy P., Dash A.. Preparation, evaluation, and first clinical use of 177Lu-labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacy. J. Labelled Comp. Radiopharm. 2014;57(7):453–462. doi: 10.1002/jlcr.3202. [DOI] [PubMed] [Google Scholar]
  22. Brady E. D., Chong H. S., Milenic D. E., Brechbiel M. W.. Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. Nucl. Med. Biol. 2004;31(6):795–802. doi: 10.1016/j.nucmedbio.2004.04.004. [DOI] [PubMed] [Google Scholar]
  23. Al-Ejeh F., Darby J. M., Thierry B., Brown M. P.. A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution. Nucl. Med. Biol. 2009;36(4):395–402. doi: 10.1016/j.nucmedbio.2009.01.001. [DOI] [PubMed] [Google Scholar]
  24. Costantini D. L., Chan C., Cai Z., Vallis K. A., Reilly R. M.. (111)­In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J. Nucl. Med. 2007;48(8):1357–1368. doi: 10.2967/jnumed.106.037937. [DOI] [PubMed] [Google Scholar]
  25. Akabani G., Carlin S., Welsh P., Zalutsky M. R.. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl. Med. Biol. 2006;33(3):333–347. doi: 10.1016/j.nucmedbio.2005.12.006. [DOI] [PubMed] [Google Scholar]
  26. Amirdhanayagam J., Guleria M., Sharma R., Kumar N., Mukherjee A., Das T.. Formulation of patient dose of [177Lu]­Lu-Trastuzumab using in-house developed freeze-dried kit: A path forward for clinical translation. J. Label. Compd. Radiopharm. 2024;67(4):131–144. doi: 10.1002/jlcr.4086. [DOI] [PubMed] [Google Scholar]
  27. Lub-de Hooge M. N., Kosterink J. G., Perik P. J., Nijnuis H., Tran L., Bart J., Suurmeijer A. J., de Jong S., Jager P. L., de Vries E. G.. Preclinical characterisation of 111In-DTPA-trastuzumab. Br. J. Pharmacol. 2004;143(1):99–106. doi: 10.1038/sj.bjp.0705915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Price E. W., Edwards K. J., Carnazza K. E., Carlin S. D., Zeglis B. M., Adam M. J., Orvig C., Lewis J. S.. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal 90Y. Nucl. Med. Biol. 2016;43(9):566–576. doi: 10.1016/j.nucmedbio.2016.06.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Kameswaran M., Gota V., Ambade R., Gupta S., Dash A.. Preparation and preclinical evaluation of 131I-trastuzumab for breast cancer. J. Label. Compd. Radiopharm. 2017;60(1):12–19. doi: 10.1002/jlcr.3465. [DOI] [PubMed] [Google Scholar]
  30. Haberkorn U., Giesel F., Morgenstern A., Kratochwil C.. The Future of Radioligand Therapy: α, β, or Both? J. Nucl. Med. 2017;58(7):1017–1018. doi: 10.2967/jnumed.117.190124. [DOI] [PubMed] [Google Scholar]
  31. Shen H., Zhang M., Kaita K., Minuk G. Y., Rempel J., Gong Y.. Expression of Fc Fragment Receptors of Immunoglobulin G (FcγRs) in Rat Hepatic Stellate Cells. Dig. Dis. Sci. 2005;50(1):181–187. doi: 10.1007/s10620-005-1298-5. [DOI] [PubMed] [Google Scholar]
  32. Løvdal T., Andersen E., Brech A., Berg T.. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J. Cell. Sci. 2000;113:3255–3266. doi: 10.1242/jcs.113.18.3255. [DOI] [PubMed] [Google Scholar]
  33. Kumar N., Sharma A., Guleria M., Shelar S. B., Chakraborty A., Rakshit S., Kolay S., Satpati D., Das T.. Enhancing the tumor uptake and therapeutic potency of [177Lu]­Lu-labeled porphyrin derivative by conjugation with nuclear localization signal (NLS) sequence: a systemic in-vitro and ex-vivo evaluation. Mol. Pharmaceutics. 2024;21(5):2351–2364. doi: 10.1021/acs.molpharmaceut.3c01152. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ml5c00472_si_001.pdf (159.1KB, pdf)

Articles from ACS Medicinal Chemistry Letters are provided here courtesy of American Chemical Society

RESOURCES